4 patents currently held
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2037. from the record
Of the 14 now held by other companies, 14 name Biokine Therapeutics Ltd. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2037
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2037 · High confidence
Also notable
Ends Feb 2037 · High confidence
Also notable
Ends Jan 2040 · High confidence
Compositions, Articles of Manufacture and Methods for Treating Cancer
US 10,786,547
The most cited patent in this portfolio, cited by 24 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2037.
Methods of Treating Acute Myeloid Leukemia
US 10,993,985
Cited by 14 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2037.
Treatment of Metastatic Pancreatic Adenocarcinoma
US 12,291,570
Granted 2025. Too new for citation comparison; protection runs to 2040.
Formerly held, still cited
Notable
Ends Jan 2037 · High confidence
Cited by 17 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
now held by Biokine Therapeutics Ltd.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Process for Manufacturing Peptide | 1 in force | to Dec 2041 |
| Treatment of Metastatic Pancreatic Adenocarcinoma | 1 in force | to Jan 2040 |
| Methods of Treating Acute Myeloid Leukemia | 1 in force | to Feb 2037 |
| Compositions, Articles of Manufacture and Methods for Treating Cancer | 1 in force | to Jan 2037 |
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,786,547 | Compositions, Articles of Manufacture and Methods for Treating Cancer In force · High confidence | In force | High confidence | |
| US 10,993,985 | Methods of Treating Acute Myeloid Leukemia In force · High confidence | In force | High confidence | |
| US 12,291,570 | Treatment of Metastatic Pancreatic Adenocarcinoma held by Biolinerx Ltd. and Merck Sharp & Dohme Corp. In force · High confidence | In force | High confidence | |
| US 11,993,631 | Process for Manufacturing Peptide held by Biolinerx Ltd. and Biokine Therapeutics Ltd. In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 14 patents in force now held by others · 4 patents ended · 9 applications pending · 26 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.